Last reviewed · How we verify

Propofol MCT

Chung-Ang University Gwangmyeong Hospital · FDA-approved active Small molecule

Propofol MCT is a medium-chain triglyceride formulation of propofol that acts as a positive allosteric modulator of GABA-A receptors to produce rapid sedation and anesthesia.

Propofol MCT is a medium-chain triglyceride formulation of propofol that acts as a positive allosteric modulator of GABA-A receptors to produce rapid sedation and anesthesia. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units.

At a glance

Generic namePropofol MCT
SponsorChung-Ang University Gwangmyeong Hospital
Drug classGeneral anesthetic
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Propofol enhances inhibitory GABAergic neurotransmission in the central nervous system, leading to sedation, hypnosis, and anesthesia. The MCT (medium-chain triglyceride) formulation improves the pharmacokinetic profile and reduces pain on injection compared to the standard lipid emulsion formulation. This formulation allows for more rapid onset and offset of anesthetic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: